| Symbol | AIM |
|---|---|
| Name | AIM IMMUNOTECH INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 2117 SW HIGHWAY 484, OCALA, FL 32801 |
| Telephone | 352-448-7797 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | None |
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
Read moreNew Form 424B5 - AIM ImmunoTech Inc. <b>Filed:</b> 2026-04-10 <b>AccNo:</b> 0001493152-26-016176 <b>Size:</b> 18 KB
Read moreAIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
Read moreNew Form 10-K - AIM ImmunoTech Inc. <b>Filed:</b> 2026-03-27 <b>AccNo:</b> 0001493152-26-013301 <b>Size:</b> 11 MB
Read moreAIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
Read moreEquels Thomas K 🟢 acquired 50.0K shares (2 derivative) of AIM ImmunoTech Inc. (AIM) at $1,000.00 Transaction Date: Mar 06, 2026 | Filing ID: 009587
Read moreDirector CHEMEROW DAVID I. 🟢 acquired 50.0K shares (2 derivative) of AIM ImmunoTech Inc. (AIM) at $1,000.00 Transaction Date: Mar 06, 2026 | Filing ID: 009586
Read more